Tr1x, Inc.
🇺🇸United States
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Treatment of Moderate to Severe Refractory Crohn's Disease
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Tr1X, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06721962
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸Northwestern, Chicago, Illinois, United States
🇺🇸Mount Sinai Health Systems, New York, New York, United States
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1
Recruiting
- Conditions
- Hematologic MalignancyHematopoietic Stem Cell TransplantAcute Lymphoblastic Leukemia, Adult B-CellAcute Myeloid Leukemia in RemissionCancer RemissionGvHDGVHD, ChronicMyelodysplastic SyndromesGVHD,AcuteAcute Lymphoblastic Leukemia, Adult T-Cell
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Tr1X, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06462365
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸City of Hope, Duarte, California, United States
News
No news found